ORIGINAL PAPER
Prognostic factors related with prolonged hospital stay in community-acquired pneumonia
 
More details
Hide details
1
6th Respiratory Department, Sotiria Chest Diseases Hospital, Athens, Greece
2
Department of Pneumology, Hospital Clinic of Barcelona; August Pi i Sunyer Biomedical Research Institute - IDIBAPS, University of Barcelona; Biomedical Research Networking Centres in Respiratory Diseases
CORRESPONDING AUTHOR
Adamantia Liapikou   

Respiratory Medicine, 6th Respiratory Department, Sotiria Chest Diseases Hospital, 152 Mesogion Avenue, GR-11527, Athens, Greece
 
Pneumon 2019;32(3):81–88
 
KEYWORDS
ABSTRACT
Background:
Community-acquired pneumonia (CAP) is associated with higher morbidity, mortality and economic burden among adults. The cost of the disease increases according to the site of care (home, ward, ICU) and the length of hospital stay (LOS). The early recognition of prognostic factors for prolongs hospital stay it will be helpful to decrease the cost of CAP.

Methods:
A prospective observational study of consecutive CAP patients was performed at Sotiria Hospital of Athens-Greece, between June 2011-July 2018. We divided the population in two groups: prolonged length of stay (PLOS) group (hospitalization equal or higher than the mean LOS) and short length of stay (SLOS) group (less than the mean LOS).

Results:
Of a total 930 patients (55% men, 63.7 years (SD 18) with a mean length of hospital stay of 11 days (SD 9.6), 286 patients has PLOS of 20 days (SD 13). The patients with PLOS were older (66 y vs. 63y, p=0.023) and had received more often antibiotics before admission (53% vs. 44%, p=0.015). They presented with more severe CAP according to PSI score (115 vs. 98, p<0.001). The clinical evolution was more often complicated with systemic complications (43% vs. 19%, p<0.001) and need for ICU (14% vs. 6%, p<0.001) admission, but not with higher mortality.

Conclusions:
In the multivariate analysis, the severity of CAP (PSI class >4),previous antibiotics, hypoalbuminemia, therapy with corticosteroids, pulmonary complications and the non-adherence to guidelines are significantly related with prolonged hospitalization for CAP.

 
REFERENCES (33)
1.
Cilloniz C, Rodriguez-Hurtado D, Torres A. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. Med Sci Basel Switz 2018; 6.
 
2.
Welte T, Torres A, Nathwani D. Clinical and economic burden of community acquired pneumonia among adults in Europe. Thorax 2012; 67:71–9.
 
3.
Rozenbaum MH, Mangen M-JJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine 2015; 33:3193–9.
 
4.
Menendez R, Cremades MJ, Martinez-Moragon E, Soler JJ, Reyes S, Perpina M. Duration of length of stay in pneumonia: Influence of clinical factors and hospital type. Eur Respir J 2003; 22:643-8.
 
5.
McGregor MJ, Fitzgerald JM, Reid RJ, et al. Determinants of hospital length of stay among patients with pneumonia admitted to a large Canadian hospital from 1991 to 2001. Can Respir J 2005; 12:365–70.
 
6.
Capelastegui A, Espana PP, Quintana JM, et al. Declining length of hospital stay for pneumonia and post discharge outcomes. Am J Med 2008; 121:845–52.
 
7.
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27–S72.
 
8.
Cilloniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 2013; 144:999–1007.
 
9.
Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377–82.
 
10.
Garau J, Baquero F, Perez-Trallero E, et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008; 14:322–9.
 
11.
Cabre M, Bolivar I, Pera G, Pallares R; Pneumonia Study Collaborative Group. Factors influencing length of hospital stay in community-acquired pneumonia: a study in 27 community hospitals. Epidemiol Infect 2004; 132:821–9.
 
12.
Huang JQ, Hooper PM, Marrie TJ. Factors associated with length of stay in hospital for suspected community-acquired pneumonia. Can Respir J 2006; 13:317-24.
 
13.
Burns LR, Wholey DR. The effects of patient, hospital, and physician characteristics on length of stay and mortality. Med Care 1991; 29:251–71.
 
14.
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243–50.
 
15.
ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307:2526–33.
 
16.
Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30:536–55.
 
17.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care Lond Engl 2004; 8:R204-12.
 
18.
Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340–6.
 
19.
Feagan BG, Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK. Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. Can Med Assoc J 2000; 162:1415–20.
 
20.
Amaro R, Sellares J, Polverino E, et al. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia. J Infect. 2017; 74:442-9.
 
21.
Schaaf B, Kruse J, Rupp J, et al. Sepsis severity predicts outcome in community acquired pneumococcal pneumonia. Eur Respir J 2007; 30:517-24.
 
22.
Kruger S, Ewig S, Kunde J, et al. Assessment of inflammatory markers in patients with community-acquired pneumonia-influence of antimicrobial pretreatment: results from the German competence network CAPNETZ. Clin Chim Acta 2010; 411:1929-34.
 
23.
Suter-WidmerHYPERLINK “https://www.ncbi.nlm.nih.gov/p...” I, ChristCrain M, Zimmerli W, Albrich W, Mueller B, Schuetz P; ProHOSP Study Group. Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study. BMC HYPERLINK “https://www.ncbi.nlm.nih.gov/p...https://www.ncbi.nlm.nih.gov/p.... 2012 May 20; 12:21
 
24.
Waterer G. Empiric antibiotics for community-acquired pneumonia: A macrolide and a beta-lactam please! Respirology 2018; 23:450-1.
 
25.
Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: Link between quality of care and resource utilization. Arch Intern Med 2002; 162:682-8.
 
26.
McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guidelineconcordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009; 169:1525–31.
 
27.
Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005; 143:881-94.
 
28.
Arnold FW, La Joie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009; 169:1515–24.
 
29.
Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313:677-86.
 
30.
Briel M, Spoorenberg SMC, Snijders D, et al; Ovidius Study Group; Capisce Study Group; STEP Study Group. Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Meta-analysis. Clin Infect Dis 2018; 66:346-54.
 
31.
Menendez R, Ferrando D, Valles JM, Martinez E, Perpina M. Initial risk class and length of hospital stay in community-acquired pneumonia. Eur Respir J 2001;18:151-6.
 
32.
Cilloniz C, Ewig S, Polverino E, et al. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes. Clin Microbiol Infect 2012; 18:1134-42.
 
33.
Mundy LM, Leet TL, Darst K, Schnitzler MA, Dunagan WC. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124:883-9.
 
eISSN:1791-4914
ISSN:1105-848X